Healthcare
Jinxin Fertility Group Limited(JXFGF)
Live Price
Offline$0.29
+0.00% today
1Y Change
+3.57%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $5.53B
- Revenue Growth
- -8.2%
- EPS Growth
- -418.2%
- Dividend Yield
- 0.0%
Coverage: 255 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jinxin Fertility Group Limited (JXFGF) is a Healthcare stock with a market cap of $5.53B and listed on OTC. The stock last traded around $0.29 and up 3.6% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -8.2%, EPS growth of -418.2%, a dividend yield of 0.0%. What stands out right now is revenue -8.2%, EPS -418.2%, free cash flow -40.5% with operating margin 3.9% and ROIC 0.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines JXFGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-8.2% vs +7.6% peer median
Operating Margin
Below sector median
+3.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 1, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -8.2% and EPS is at -418.2%, with operating margin around 3.9%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 1, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 26, 2026 | +0.0% | +0.0% | +0.0% | +0.0% |
2025 Aug 25, 2025 | -875.6% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
JXFGF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JXFGF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JXFGF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JXFGF and SPY.
Company Overview
Jinxin Fertility Group Limited
Other OTC
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.
- Leadership
- Yang Dong
- IPO Date
- Jun 25, 2021
- Employees
- 3.2k
- Street Address
- No. 301, North Jingsha Road
- Mailing
- Chengdu
- Region
- Chengdu, CN
- Reporting Currency
- USD
- Investor Line
- 86 40 0042 6868
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 18.6
- Price/Sales
- 2.1
- Price/Book
- 0.5
Growth
- Revenue
- -8.2%
- EPS
- -418.2%
- Free Cash Flow
- -40.5%
Profitability
- Gross Margin
- 32.6%
- Operating Margin
- 3.9%
- Net Margin
- -37.2%
- ROE
- -10.7%
- ROIC
- 0.8%
Balance Sheet
- Debt/Equity
- 0.32
- Current Ratio
- 0.87
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.